Expanded Access Treatment Protocol: Remdesivir (RDV) for the Treatment of SARS-CoV2 (CoV) Infection

About this Study

Expanded access treatment protocol for use of RDV for the treatment of a participant with coronavirus disease-2019 (COVID-19) resulting from infection of SARS-CoV-2.


*UMMC is currently prescribing RDV for COVID-19 patients under the emergency use authorization as opposed to the expanded access treatment protocol.*

Sponsor Protocol ID:GS-5734
IRB Number:2020-0128
Closed for Enrollment
Interventional
Observational/Not Applicable
April 16, 2020
Eligibility Criteria
18 years old
Both Male and Female
No
No
No

Inclusion Criteria(1) Age ≥ 18 years or aged ≥ 12 and
(2) Hospitalized with confirmed SARS-CoV2 by PCR or known contact of confirmed case with syndrome consistent with COVID-19 with PCR pending; 
(4) Requiring invasive mechanical ventilation; and
(5) ALT ≤ 5 × upper limit of normal by local lab measure.

Exclusion Criteria(1) Evidence of multi-organ failure; 
(2) Use of more than 1 pressor for septic shock; 
(3) Renal failure; and
(4) Known hypersensitivity to the study drug.

(Protocol silent on dual enrollment).

Categories Click category to view its trials.
COVID-19 (Coronavirus)
Participating Locations
University Hospital - UMMC
Contact Information
Contact Name: David Cretella
Phone Number: 601-815-2721
Email: dcretella@umc.edu
Principal Investigator:Parham, Jason, M.D.
How to participate in our Clinical Trials